Key points
- First patient safely dosed in TACTI-004 Phase III lung cancer trial
- Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025
- Patient enrolment completed for the EFTISARC-NEO Phase II and INSIGHT-003 Phase I trials
- Strong cash position of A$146.25 million, providing an expected cash reach to the end of CY2026
Full summary
Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies, provides an update on its activities for the quarter ended 31 March 2025 (Q3 FY25). Key highlights include:EFTI DEVELOPMENT PROGRAM FOR CANCER:- First patient successfully dosed in the pivotal TACTI-004 Phase III trial evaluating efti in combination with KEYTRUDA and chemotherapy as first-line treatment of advanced or metastatic non-small cell lung cancer (1L NSCLC).- Immutep presented the TACTI-004 trial design at the European Lung Cancer Congress (ELCC) 2025.- Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating efti with radiotherapy and KEYTRUDA in resectable soft tissue sarcoma, and the INSIGHT-003 Phase I trial evaluating efti with KEYTRUDA and chemotherapy as first-line treatment of advanced or metastatic 1L NSCLC.IMP761 DEVELOPMENT PROGRAM FOR AUTOIMMUNE DISEASE:- Ongoing Phase I trial of autoimmune candidate IMP761, with additional safety data and PK/PD assessment expected in CY2025.INTELLECTUAL PROPERTY:- Granted two new patents for LAG525 in the Philippines and the United States, and a Russian patent for an assay to measure the potency of IMP761.CASH FLOW SUMMARY:- Strong cash position of approximately A$146.25 million as of 31 March 2025, providing an expected cash reach to the end of CY2026.
Guidance
Immutep is well funded with a strong cash and cash equivalent, and term deposit balance as at 31 March 2025 of approximately A$146.25 million, which is greater than budgeted and provides an expected cash reach to the end of CY2026.